CervoMed (CRVO) Operating Expenses (2010 - 2026)

CervoMed has reported Operating Expenses for 17 years, with the latest figure at $8.1 million in Q1 2026.

• Quarterly Operating Expenses rose 12.33% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.2 million (up 9.75% YoY) and the FY2025 annual result came in at $32.3 million, up 15.51% from the prior year.
• Operating Expenses eased to $8.1 million in Q1 2026 per CRVO's latest filing, from $8.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $9.4 million in Q4 2024 and troughed at $904054.0 in Q3 2022.
• A 5-year average of $5.5 million and a median of $5.0 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses plunged 77.71% in 2022, then jumped 429.5% in 2023.
• Over 5 years, Operating Expenses stood at $938823.0 in 2022, then surged by 429.5% to $5.0 million in 2023, then surged by 89.15% to $9.4 million in 2024, then declined by 11.3% to $8.3 million in 2025, then declined by 2.75% to $8.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $8.1 million, $8.3 million, and $8.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.